Mehmet Kemal Samur

Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.

Kurata K, Samur MK, Liow P, Wen K, Yamamoto L, Liu J, Morelli E, Gulla A, Tai YT, Qi J, Hideshima T, Anderson KC.

Clin Cancer Res. 2024 Sep 03. 30(17):3956. PMID: 39224021

Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.

Deng S, Derebail S, Weiler VJ, Fong Ng J, Maroto-Martin E, Chatterjee M, Giorgetti G, Chakraborty C, Kalhotra P, Du T, Yao Y, Prabhala R, Shammas M, Gulla A, Aktas Samur A, Samur MK, Qiu L, Anderson KC, Fulciniti M, Munshi NC.

Blood Adv. 2024 Aug 13. 8(15):4025-4034. PMID: 38861273

RAS/RAF landscape in monoclonal plasma cell conditions.

Schavgoulidze A, Corre J, Samur MK, Mazzotti C, Pavageau L, Perrot A, Cazaubiel T, Leleu X, Macro M, Belhadj K, Roussel M, Brechignac S, Montes L, Caillot D, Frenzel L, Rey P, Schiano de Colella JM, Chalopin T, Jacquet C, Richez V, Orsini-Piocelle F, Fontan J, Manier S, Martinet L, Sciambi A, Mohty M, Avet-Loiseau H.

Blood. 2024 Jul 11. 144(2):201-205. PMID: 38643494

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.

Gulla A, Morelli E, Johnstone M, Turi M, Samur MK, Botta C, Cifric S, Folino P, Vinaixa D, Barello F, Clericuzio C, Favasuli VK, Maisano D, Talluri S, Prabhala R, Bianchi G, Fulciniti M, Wen K, Kurata K, Liu J, Penailillo J, Bragoni A, Sapino A, Richardson PG, Chauhan D, Carrasco RD, Hideshima T, Munshi NC, Anderson KC.

Blood. 2024 Jun 20. 143(25):2612-2626. PMID: 38551812

Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications.

Letouzé E, Moreau P, Munshi N, Samur M, Minvielle S, Touzeau C.

Blood Adv. 2024 Jun 11. 8(11):2952-2959. PMID: 38513088

Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes.

Binder M, Szalat RE, Talluri S, Fulciniti M, Avet-Loiseau H, Parmigiani G, Samur MK, Munshi NC.

Nat Commun. 2024 May 16. 15(1):4139. PMID: 38755155

ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma.

Kumar S, Talluri S, Zhao J, Liao C, Potluri LB, Buon L, Mu S, Shi J, Chakraborty C, Tai YT, Samur MK, Munshi NC, Shammas MA.

Blood. 2024 Mar 14. 143(11):996-1005. PMID: 37992230

Redefining high risk multiple myeloma with an APOBEC/Inflammation-based classifier.

Grasedieck S, Panahi A, Jarvis MC, Borzooee F, Harris RS, Larijani M, Avet-Loiseau H, Samur M, Munshi N, Song K, Rouhi A, Kuchenbauer F.

Leukemia. 2024 May. 38(5):1172-1177. PMID: 38461190

Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8aß+ T cells targeting multiple myeloma.

Bae J, Kitayama S, Herbert Z, Daheron L, Kurata K, Keskin DB, Livak K, Li S, Tarannum M, Romee R, Samur M, Munshi NC, Kaneko S, Ritz J, Anderson KC.

Blood. 2024 Mar 07. 143(10):895-911. PMID: 37890146

Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.

Prabhala R, Pierceall WE, Samur M, Potluri LB, Hong K, Peluso T, Talluri S, Wang A, Katiki A, Vangala SD, Buonopane M, Bade V, Seah H, Krogman A, Derebail S, Fulciniti M, Lazo SB, Richardson P, Anderson K, Corre J, Avet-Loiseau H, Thakurta A, Munshi N.

Front Oncol. 2023. 13:1271807. PMID: 38111533